Lyell Immunopharma (NASDAQ:LYEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a sell rating to a hold rating in a research note released on Sunday morning,Wall Street Zen reports.

LYEL has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. Stifel Nicolaus assumed coverage on shares of Lyell Immunopharma in a research report on Thursday, August 6th. They set a “buy” rating and a $36.00 target price on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a research report on Friday, September 11th. Finally, B. Riley Financial started coverage on shares of Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.86.

Lyell Immunopharma Stock Up 8.7%

NASDAQ:LYEL opened at $10.12 on Friday. The company has a 50-day moving average of $11.30 and a 200-day moving average of $17.09. Lyell Immunopharma has a 52 week low of $7.20 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($1.94) by $0.02. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Equities research analysts predict that Lyell Immunopharma will post -7.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new position in Lyell Immunopharma during the second quarter worth about $347,000. Walleye Capital LLC bought a new stake in Lyell Immunopharma in the first quarter valued at approximately $445,000. Squarepoint Ops LLC lifted its position in shares of Lyell Immunopharma by 119.4% in the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after buying an additional 23,028 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after buying an additional 25,276 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Lyell Immunopharma in the first quarter valued at approximately $959,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.